Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value

Executive Summary

CEO Heather Bresch gave a soliloquy on US health care during the second quarter call, saying ‘perverse incentives’ have created a system that ‘feeds on higher prices.’

Advertisement

Related Content

Teva To Launch First Generic EpiPen In 'Coming Months'; FDA Heralds Approval Of Complex Product
Enthusiasm For US Biosimilars Wanes For Some, But Not Others
Generic Drug Sector Struggles Even As The Need For Cheaper Drugs Grows
Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?
Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone
The Quality Lowdown: Cleaning Issues At Mylan, Blank Release Forms At API Plant In China, And More
Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel